Jennifer Scott Perry net worth and biography

Jennifer Perry Biography and Net Worth

Jennifer Perry, Pharm.D. is the chief operating officer at Bicycle Therapeutics.

Jennifer has over 20 years of experience in biotech and the pharmaceutical industry, with 15 years in oncology. She has devoted much of her career to building and leading oncology teams focused on the critical steps to commercialization. Her experience spans commercial and medical roles with a focus on go-to-market strategies for launching oncology medicines at GlaxoSmithKline, Tesaro, TG Therapeutics and Pharmacyclics. Most recently, she built and led U.S. oncology sales teams for hematology and solid tumors at TG Therapeutics and at GSK/Tesaro, with responsibility for leading the customer-selling strategy and driving the achievement of U.S. sales targets.

Jennifer also brings a significant breadth of experience across additional commercialization roles including a deep medical affairs background leading Field Medical, Medical Strategy, Medical Information and Scientific Communications. This experience includes launching novel blockbuster oncology therapies throughout her career in leukemia, lymphoma, ovarian cancer and melanoma.

Jennifer attended Loyola University Chicago for her undergraduate education and received her Pharm.D. from the University of Illinois Chicago.

What is Jennifer Scott Perry's net worth?: The estimated net worth of Jennifer Scott Perry is at least $454.89 thousand as of April 2nd, 2026. Perry owns 92,834 shares of Bicycle Therapeutics stock worth more than $454,887 as of May 5th. This net worth estimate does not reflect any other assets that Perry may own. Learn More about Jennifer Scott Perry's net worth.
How do I contact Jennifer Scott Perry?: The corporate mailing address for Perry and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Jennifer Scott Perry's contact information.
Has Jennifer Scott Perry been buying or selling shares of Bicycle Therapeutics?: In the last ninety days, Jennifer Scott Perry has sold $6,961.38 in shares of Bicycle Therapeutics stock. Most recently, Jennifer Scott Perry sold 370 shares of the business's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $5.04, for a transaction totalling $1,864.80. Following the completion of the sale, the chief operating officer now directly owns 92,464 shares of the company's stock, valued at $466,018.56. Learn More on Jennifer Scott Perry's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Santiago Arroyo (Insider), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), Pierre Legault (Director), Alistair Milnes (COO), Jennifer Perry (COO), Michael Skynner (CTO), Robert Swanton (Director), Travis Thompson (CAO), and Alethia Young (CFO). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, insiders at the sold shares 29 times. They sold a total of 64,634 shares worth more than $431,887.68. The most recent insider tranaction occured on April, 6th when CFO Travis Alvin Thompson sold 102 shares worth more than $515.10. Insiders at Bicycle Therapeutics own 22.9% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 4/6/2026.

Jennifer Scott Perry Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/6/2026	Sell	370	$5.04	$1,864.80	92,464
4/2/2026	Sell	1,038	$4.91	$5,096.58	92,834

Jennifer Scott Perry Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $4.90

$4.83

$5.08

50 Day Range

MA: $5.02

$4.31

$5.73

2 Week Range

Now: $4.90

$4.24

$9.36

Volume

318,718 shs

Average Volume

420,077 shs

Market Capitalization

$341.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56